Molecule
Telotristat ethyl is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. MedsAcross supplies Telotristat ethyl for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Source: US FDA prescribing information
Telotristat, the active metabolite of telotristat ethyl, is an inhibitor of tryptophan hydroxylase, which mediates the rate limiting step in serotonin biosynthesis. The in vitro inhibitory potency of telotristat towards tryptophan hydroxylase is 29 times higher than that of telotristat ethyl. Serotonin plays a role in mediating secretion, motility, inflammation, and sensation of the gastrointestinal tract, and is over-produced in patients with carcinoid syndrome. Through inhibition of tryptophan hydroxylase, telotristat and telotristat ethyl reduce the production of peripheral serotonin, and the frequency of carcinoid syndrome diarrhea.
Source: US FDA prescribing information
The recommended dosage of Xermelo in adult patients is 250 mg three times daily for patients whose diarrhea is inadequately controlled by SSA therapy. Administration Take Xermelo with food. When short-acting octreotide is used in combination with Xermelo, administer short-acting octreotide at least 30 minutes after administering Xermelo. If a dose is missed, take the next dose at the regular time. Do not take 2 doses at the same time to make up for a missed dose. Discontinue Xermelo if severe constipation develops. The recommended dosage of Xermelo in adult patients is 250 mg three times daily for patients whose diarrhea is inadequately controlled by a SSA therapy. Take Xermelo with food.
Source: US FDA prescribing information
Xermelo is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritus. History of hypersensitivity to telotristat.
Source: US FDA prescribing information
Constipation: Xermelo reduces bowel movement frequency, monitor patients for constipation, and/or severe persistent or worsening abdominal pain. Discontinue Xermelo if constipation or abdominal pain develops.
Source: US FDA prescribing information
Most common adverse reactions (≥5%) are nausea, headache, increased GGT, depression, flatulence, decreased appetite, peripheral edema, and pyrexia.
Source: US FDA prescribing information
CYP3A4 Substrates (e.g., midazolam) and CYP2B6 Substrates (e.g., bupropion, efavirenz): Efficacy of concomitant drugs may be decreased, monitor patients’ response and consider increasing the dosage of the concomitant drug, if necessary.
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Telotristat ethyl, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Xermelo 250 mg tabletOral | TerSera Therapeutics | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Telotristat ethyl in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Telotristat ethyl and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Telotristat ethyl, including Xermelo.
Yes. Telotristat ethyl has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Telotristat ethyl is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Telotristat ethyl is classified under ATC code A16A (Metabolic disease treatments, including enzyme replacement, subgroup A16A).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.